(lp0
S"The 3 Most Important Numbers for Exelixis, Inc. Motley Fool - Mar 14, 2017 Exelixis  boasts several numbers that make its shareholders smile. The biotech's stock has soared more than 430% over the past 12 months."
p1
aS'3 Factors That Drove Exelixis, Inc. Higher By 19% in February Motley Fool - Mar 7, 2017 Shares of Exelixis , a biopharmaceutical company focused on the development of medicines for the treatment of cancer, surged 19% in February, according to data from S&amp;P Global Market Intelligence.'
p2
aS"Exelixis, Inc. Turns a Profit, but Don't Get Too Excited Motley Fool - Mar 1, 2017 Exelixis  reported fourth-quarter earnings on Monday showing solid growth in sales of Cabometyx. The biotech reported a profit for the quarter, but there were some extenuating circumstances that helped push Exelixis into the black.Company Update : Exelixis, Inc. Announces Clinical Trial ... - Smarter AnalystExelixis Announces Webcasts of Investor Conference Presentations in March - Yahoo Finance"
p3
aS'Exelixis, Inc.  Forecasted to Post Q1 2017 Earnings of  Per Share BNB Daily  - Mar 20, 2017 Exelixis logo Exelixis, Inc.  - Equities research analysts at Oppenheimer Holdings issued their Q1 2017 earnings estimates for Exelixis in a report issued on Wednesday.The Exelixis, Inc.  Director Charles Cohen Sells 10000 Shares - Petro Global News 24Featured Stock for Investors: Exelixis, Inc.  - HugoPress'
p4
aS'Earnings Clues on Exact Sciences Corporation , Exelixis, Inc. (EXEL ... StockNewsJournal - 18 hours ago Exelixis, Inc. , at its latest closing price of $22.03, it has a price-to-book ratio of 70.92, compared to an industry average at 10.38.'
p5
aS"Exelixis, Inc.  Receives FDA Orphan Drug Designation for the Treatment ... Smarter Analyst - Mar 6, 2017 Exelixis, Inc.  announced that the FDA has granted orphan drug designation to cabozantinib for the treatment of hepatocellular carcinoma .Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of ... - Business Wire "
p6
aS"Form 4 EXELIXIS, INC. For: Mar 01 Filed by: POSTE GEORGE StreetInsider.com - Mar 4, 2017 Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here. FORM 4, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C."
p7
aS'No More Ambiguity, Exelixis, Inc.  And Its Chart Is Now Crystal Clear NY Stock News - 13 hours ago The technicals for Exelixis, Inc.  has spoken via its technical chart and the message is loud and clear. Based on that message, this is the relevant information necessary to make sense of that current setup.'
p8
aS'Revenue Approximations Analysis: Pandora Media, Inc. , Exelixis, Inc.  StockNewsJournal - Mar 16, 2017 Exelixis, Inc. , at its latest closing price of $22.80, it has a price-to-book ratio of 71.41, compared to an industry average at 9.98.Unusual Volume Spikes For: Exelixis, Inc.  - Normangee StarInsider Trading Activity Exelixis, Inc.   Director Sold 10000 ... - Market Exclusive'
p9
aS"Equity Perception: Analyst's Indicator Review for Cousins Properties ... The USA Commerce - Mar 15, 2017 Shares of Cousins Properties Incorporated  dropped -1.00% to $7.94. During the trading on 03/14/2017, Company's stock ranged from $7.87 to $8.02.Analysts Stance on 2 Companies: Cousins Properties Incorporated (NYSE:CUZ ... - The Voice RegistrarHow much upside really exists in Cousins Properties Incorporated  and ... - USA Commerce Daily"
p10
a.